Biologic therapies for juvenile arthritis

Archives of Disease in Childhood

Volumn 88, Issue 3, 2003, Pages 186-191

  Wilkinson, N ^a   Jackson, G ^b   Gardner Medwin, J ^c  

^a Department of Neurosurgery   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; IMMUNOLOGIC AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 10; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; APLASTIC ANEMIA; AUTOIMMUNITY; DEMYELINATING DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG RECEPTOR BINDING; HEADACHE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MEDICAL ETHICS; NAUSEA; PANCYTOPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VOMITING;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNITY; BIOLOGICAL THERAPY; CHILD; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; INTERLEUKINS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037374358     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.3.186     Document Type: Review

References (75)

1. Gare BA. Epidemiology. Boillieres Clin Rheumotol 1998;12:191-208.
2. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexote in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind placebo controlled trial. N Engl J Med 1992;326:1043-9.
3. Giannini EH, Newman AJ, Fink CW. Low dose methotrexote in children with juvenile rheumatois arthritis: results of a post-trial, long-term follow-up program [abstract]. Arthritis Rheum 1993;36:S54.
4. Wallace CA. The use of methotrexate in childhood rheumotic diseoses. Arthritis Rheum 1998;41:381-9.
5. Wallace CA. On beyond methotrexate: treatment of severe juvenile rheumatoid arthritis. Clin Exp Rheum 1999;17:499-504.
6. Martin K, Woo P. Outcome in JCA. Rev Rheum 1997;5242.
7. Strax TE. Psychological issues faced by adolescents ond young adults with disobilities. Pediatr Ann 1991;20:501-6.
8. Dighiero G, Rose NR. Criticol self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Todoy 1999;20:423-8.
9. Goldrath AW, Bevan MJ. Selecting and mointaining o diverse T-cell repertoire. Nature 1999;402:255-62.
10. Gu H, Tarlinton D, Muller W, et al. Most peripherol B cells in mice ore ligand selected. J Exp Med 1991;173:1357-71
11. Silverstein AM, Rose NR. There is only one immune system! The view from immunopothology. Semin Immunol 2000;12:173-8, 257-344.
12. Thomas R, Lipsky PE. Could endogenous self-peptides presented by dendritic cells initiate rheumatoid orthritis? Immunol Todoy 1996;17:559-64.
13. Kourilsky P, Truffa-Bachi P. Cytokine fields and the polarisotion of the immune response. Trends Immunol 2001;22:505-9.
14. Panayi GS, Corrigoll VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells ond other beosts. Rheum Dis Clin North Am 2001;27:317-34.
15. Edwards JC, Combridge G, Abrohams VM. Do self-perpetuating B lymphocytes drive human autoimmune diseose? Immunology 1999;97:188-96.
16. Yetgin S, Ozen S, Saatci U, et al. Evaluation of tumour necrosis factor alpho, interferon gamma and granulocyte-macrophage colony stimulating factor levels in juvenile chronic orthritis. Rheumatology 1999;38:468-71.
17. Rooney M, David J, Symons J, et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
18. Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumour necrosis factor alpha, tumor necrosis factor beta and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum 1996;39:1703-10.
19. Rooney M, Varsani H, Martin K, et al. Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis. Rheumatology 2000;39:432-8.
20. van den Berg WB, Joosten LA, Kollias G, et al. Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1 beta in chronicity and cartilage destruction. Ann Rheum Dis 1999;58(suppl 1):140-8.
21. Date Y, Seki N, Kamizono S, et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNF alpha gene and HLA genes. Arthritis Rheum 1999;42:2577-82.
22. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
23. Almawi WY, Beyhum HN, Rahme AA, et al. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996;60:563-72.
24. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulating human monocytes. J Exp Med 1991;173:699-703.
25. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2:506-15.
26. Xu X, Williams JW, Bremer EG, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995;270:12398-403.
27. Rothman D, Smith K, Kimura Y. Safety and efficacy of etanercept (enbrel) in children with JRA less than 4 years of age [abstract 1435]. Arthritis Rheum 2001;44:S293.
28. Vinje E, Obiora O, Forre. Juvenile chronic polyarthritis treated with infliximab [abstract 745]. Ann Rheum Dis 2000;59.
29. Billiau AD, Wouters C. Improved articular and systemic disease in a boy treated with anti-TNFa monoclonal antibody (Remicade) for refractory JIA [abstract 744]. Ann Rheum Dis 2000; 59.
30. Gerloni V, Pontikaki I, Desiati F, et al. Infliximab in the treatment of persistently active refractory juvenile idiopathic arthritis. Ann Rheum Dis 2000;59:740.
31. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
32. Lovell DJ, Giannini EH, Reiff A, et al, for the Paediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
33. Lovell DJ, Giannini EH, Passo M, et al. Long-term efficacy of etanercept (ENBREL) in children with polyarticular-course juvenile rheumatoid arthritis [poster]. PRES, 2001.
34. Giannini EH, Lovell DJ, Felson DT, et al. Preliminary core set of outcome variables for use in juvenile rheumatoid arthritis clinical trials. Arthritis Rheum 1994;37:S428.
35. Giannini EH, Ruperto N, Rovelli A, et ol. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
36. Kietz DA, Pepmueller PH, Moore TL. Clinical response to etanercept in polyarticular course juvenile rheumatoid orthritis. J Rheumatol 2001;28:360-2.
37. Reiff A, Henrickson M. Prolonged efficacy of etonercept in refractory juvenile ankylosing spondylitis [abstract 1434]. Arthritis Rheum 2001;44:S292.
38. Brunner HI, Tomasi AL, Sherrard TM, et al. Effectiveness ond safety of etonercept for the treatment of juvenile rheumatoid arthritis (JRA) in clinical proctice [obstract 1436]. Arthritis Rheum 2001;44:S292.
39. Kimura Y, Imundo LF, Li SC. High dose infliximab in the treatment of resistant systemic juvenile rheumotoid orthritis [obstract 1316]. Arthritis Rheum 2001;44:S272.
40. Striegel KH, Onel KB, Lehman TJA. Leukopenia in children receiving sulfosalazine and etonercept in combinotion [obstroct 1437]. Arthritis Rheum 2001;44: S292.
41. Cush JJ, Spiero R. Etanercept update on recent "dear doctor" safety letter. ACR Hotline, 5 Dec 2000.
42. Brandt J, Hoibel H, Reddig J, et ol. Anti-TNF alpho treatment of patients with severe ankylosing spondylitis-a one yeor follow-up [abstract 208)]. Arthritis Rheum 2000;43:S101.
43. Klareskog L, Moreland LM, Cohen SB, et al. Globol safety and efficacy of up to five years of etanercept (Enbrel) theropy [abstroct 150]. Arthritis Rheum 2001;44:S77.
44. Wallis WJ, Burge DJ, Sobath D, et al. Tuberculosis reports with Etanercept (Enbrel) theropy [obstroct 153]. Arthritis Rheum 2001;44:S78.
45. Wallis WJ, Burge DJ, Holmon J, et al. Infection reports with etanercept (Enbrel) therapy [abstract 154]. Arthritis Rheum 2001;44:S78.
46. Belostocki KB, Leibowitz E, Tai K, et ol. Infections ossociated with etanercept treatment of rheumotoid arthritis: 2 years of experience in the "reol-world" [abstract 725]. Arthritis Rheum 2001;44:S725.
47. Bandt M de, Descamps V, Meyer O. Two cases of etanercept-induced-lupus-like syndrome in RA patients [obstract 1919]. Arthritis Rheum 2001;44:S372.
48. Jones RE, Moreland LW. Tumor necrosis foctor inhibitors for rheumatoid arthritis. Bull Dis Rheum 1999;48:1-3.
49. Markham A, Lamb HM. Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
50. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13:16-22.
51. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
52. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
53. Jiang Y, McCabe D, Aitchison R, et al. Relationship of Genant scoring method with Larsen scoring method in randomized, double-blind, placebo controlled trial of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:S50.
54. Campion GV, Lebsack ME, Lookabaugh J, et al. IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
55. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991;12:404-10.
56. van Roon JA, Lafeber FP, Bijlsma JW. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001;44:3-12.
57. Ghivizzani SC, Kang R, Muzzonigro T, et al. Gene therapy for arthritis - treatment of the first three patients. Arthritis Rheum 1997;40:S223.
58. Fellowes R, Etheridge CJ, Coade S, et al. Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery. Gene Therapy 2000;7:967-77.
59. Lechman ER, Jaffurs D, Ghivizzani SC, et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorate disease in both injected and contralateral control knees. J Immunol 1999;163:2202-8.
60. Minter RM, Ferry MA, Murday ME, et al. Adenoviral delivery of human and viral IL-10 in murine sepsis. J Immunol 2001;167:1053-9.
61. De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interkleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
62. Keul R, Heinrich PC, Muller-Newen G, et al. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998;10:729-34.
63. De Benedetti F, Massa M, Pignatti P, et al. Serum soluble interleukin-6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-19.
64. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
65. Hirano T, Akira S, Taga T, et al. Biological and clinical aspects of interleukin-6. Immunol Today 1990;11:443-9.
66. Breedveld FC. Monoclonal antibodies to CD4. Rheum Dis Clin North Am 1998;24:567-78.
67. Marinova-Mutafchieva L, Williams RO, Mauri C, et al. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. Arthritis Rheum 2000;43:638-44.
68. Yocum DE, Solinger AM, Tesser J, et al. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial. J Rheumatol 1998;25:1257-62.
69. Wendling D, Racadot E, Wijdenes J, et al. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1998;25:1457-61.
70. Isaacs JD, Burrows N, Wing M, et al. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997;110:158-66.
71. Protheroe A, Edwards JC, Simmons A, et al. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology 1999;38:1150-2.
72. Chernajovsky Y, Dreja H, Daly G, et al. Immuno- and genetic therapy in autoimmune diseases. Genes & Immunity 2000;1:295-307.
73. Buchs N, di Giovine FS, Silvestri T, et al. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes & Immunity 2001;2:222-8.
74. British Paediatric Rheumatology Group. Guideline for the prescribing of biologic agents for children and young adults with juvenile idiopathic arthritis. British Paediatric Rheumatology Group, April 2000.
75. NICE. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. National Institute for Clinical Excellence, Technology Appraisal Guidance No. 35, March 2002.